Skip to main content Accessibility help

Complete response in a melanoma patient treated with imatinib

  • M C Brown (a1) and R J Casasola (a2)



Imatinib therapy has been successful in gastrointestinal stromal tumours containing mutation of the KIT gene. However, there are few reported cases of successful imatinib therapy in patients with melanoma containing KIT gene mutation or c-kit protein expression.

Methods and results:

A 52-year-old man developed metastatic melanoma from a primary melanoma in the left side of the nasopharynx. The tumour was positive for c-kit protein, and there was a KIT mutation in exon 11. He was treated with imatinib. A follow-up scan one year later showed a complete response. Treatment targeting the biological characteristics of melanoma proved successful in this patient.


Corresponding author

Address for correspondence: Dr Richard J Casasola, Oncology Department, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK E-mail:


Hide All
1Chang, AE, Karnell, LH, Menck, HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma. Cancer 1998;83:1664–78
2Cancer Research UK. Skin cancer – UK incidence statistics. In: [29 November 2010]
3Manola, J, Atkins, M, Ibrahim, J, Kirkwood, J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782–93
4Rivera, RS, Nagatsuka, H, Gunduz, M, Cengiz, B, Gunduz, E, Siar, CH et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008;452:2732
5Ugurel, S, Hildenbrand, R, Zimpfer, A, La Rosée, P, Paschka, P, Sucker, A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398–405
6Wyman, K, Atkins, MB, Prieto, V, Eton, O, McDermott, DF, Hubbard, F et al. Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005–11
7Kim, KB, Eton, O, Davis, DW, Frazier, ML, McConkey, DJ, Diwan, AH et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99:734–40
8Buchdunger, E, Cioffi, CL, Law, N, Stover, D, Ohno-Jones, S, Druker, BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139–45
9Demetri, GD, von Mehren, M, Blanke, CD, Van den Abbeele, AD, Eisenberg, B, Roberts, PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80
10van Oosterom, AT, Judson, I, Verweij, J, Stroobants, S, Donato, diPaola, E, Dimitrijevic, S et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421–3
11Verweij, J, Casali, PG, Zalcberg, J, LeCesne, A, Reichardt, P, Blay, JY et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127–34
12Rubin, BP, Heinrich, MC, Corless, CL. Gastrointestinal stromal tumour. Lancet 2007;369:1731–41
13Torres-Cabala, CA, Wang, WL, Trent, J, Yang, D, Chen, S, Galbincea, J et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009;22:1446–56
14Curtin, JA, Busam, K, Pinkel, D, Bastian, BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340–6
15Beadling, C, Jacobson-Dunlop, E, Hodi, FS, Le, C, Warrick, A, Patterson, J et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821–8
16Jiang, X, Zhou, J, Yuen, NK, Corless, CL, Heinrich, MC, Fletcher, JA et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008;14:7726–32
17Medeiros, F, Corless, CL, Duensing, A, Hornick, JL, Oliveira, AM, Heinrich, MC et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889–94


Complete response in a melanoma patient treated with imatinib

  • M C Brown (a1) and R J Casasola (a2)


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed